The aim of the present study was to investigate association of serum amino (AA) acids and metabolites of AAs with post-transplant outcome in liver transplant recipients.
Introduction
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Post-transplant outcome in adult liver transplant recipients is associated with pre-, peri-and post-transplant risk factors including Model for End-Stage Liver Disease (MELD) score (1), pre-transplant nutritional status (2), pre-(3) and post-transplant kidney (4) and heart (4) disease, post-transplant infection (5) , and venous thrombosis (6) .
A multivariate analysis by McDiarmid et al. indicated that vascular thrombosis, bowel perforation, septicemia, and re-transplantation, each independently increased the risk of patient and graft loss by 3 to 4 fold during the first 6 post-transplant months (7). Sun et al. identified MELD score >30, Intensive Care Unit stay >48 h prior to transplantation, intra-operative transfusion ≥15 units, re-transplantation, post-transplant dialysis, or reoperation as risk factors for infection during the first 3 post-transplant months (8) .
AAs have direct or indirect inflammatory, anti-inflammatory and immunomodulatory effects. Recently, we reported on an association of phenylalanine and tryptophan metabolites with activated cytomegalovirus (CMV) infection in kidney transplant recipients (9) and pre-transplant plasma kynurenine as a predictor of acute rejection in kidney transplant recipients (10) . Almost all published research on the kynurenine pathway is restricted to inflammatory responses to nervous system (11) diseases. Indoleamine 2,3-dioxygenase (IDO) degrades the essential AA tryptophan into kynurenine and other downstream metabolites that suppress effector T-cell function (12) and favor the differentiation of regulatory T cells (13) . IDO is widely distributed in mammals and is inducible preferentially by interferon (IFN)- (14) . IDO is traditionally regarded as a general suppressor of T-cell activation and mediator of immune escape in cancer (13) .
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6 creased kynurenine levels. In the study by Capuron, inflammation was associated with increases in phenylalanine concentrations (15) . In a recent study we reported on association of plasma quinolinic acid and severity of hepatic dysfunction in patients with liver cirrhosis (16) . The results showed that quinolinic acid and neopterin are more sensitive markers for severity of liver disease than established markers of inflammation such as C-reactive protein (CRP), and IL-6 and that quinolinic acid provided the most sensitive index with regard to the identification of patients with hepatic encephalopathy (16) . We also reported on an association of early post-transplant neopterin (IFN--dependent response) and one-year patient survival and bacteremia in liver transplant recipients (17). Associations of pre-and early post-transplant serum AAs and their metabolites with recipient outcome in liver transplantation have not been studied. In the present study, we investigated whether pre-transplant serum AA and AA metabolites -especially the IFN--dependent kynurenine pathway, among other risk factors, are associated with recipient survival in liver transplant recipients.
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Material and Methods
Characteristics of the study population
The retrospective study was conducted in accordance with local ethical guidelines and all individuals gave informed consent for the analysis of their plasma samples. Be- We examined the association of one-year post-transplant mortality and EAD with retransplantation, pre-transplant serum amino acid profiles, metabolites of tryptophan, albumin, neopterin and the severity of diseases (determined by MELD score) and post-transplant serum amino acids, metabolites of amino acids, neopterin, CRP and
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T 8 bacterial infections. Proportion of re-transplants was higher in non-survivors and patients with EAD (Table 1) whereas proportion of patients with hepatic encephalopathy was similar in the study groups (Table 1) . Demographic data including age, gender, original liver diseases, pre-transplant CMV, HBV, and HCV IgG status as well as kidney function were similar in survivors and nonsurvivors (Table 1 ). The number of females was significantly higher in patients with EAD (Table 1) .
Serum Separation
Serum separator tubes were centrifuged at 4000 rpm for 15 min at 4°C. Serum was collected after the blood clotting process. The serum was snap frozen and stored at -20°C until testing. All serum samples were thawed only once before testing.
Determination of serum phenylalanine, tryptophan and tryptophan metabolites (kynurenine, kynurenic acid and quinolinic acid)
Serum amino acid levels were measured by tandem mass spectrometry. For analysis of tryptophan catabolism, heparinized serum samples were drawn from peripheral veins in all patients. 100 µL of serum was analysed after addition of 10 μl
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A C C E P T E D M A N U S C R I P T 9 trichloroacetic acid (50%) (FLUKA, Germany), 60 μl water, 100 µl methanol (JT Baker, Estimated IDO-activity was assessed as previously reported (18) .
Determination of serum neopterin, CRP and albumin
Serum neopterin was measured with the Neopterin ELISA kit (Brahms, Berlin, Germany). Based on control measurements in 70 healthy individuals, serum level of >15 nmol/L was considered abnormally high. The protocol provided by the assay manufacturer was strictly followed. Serum CRP and albumin were assessed in a certified laboratory at Heidelberg University Hospital.
Statistical analysis
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Increased pre-transplant serum levels of phenylalanine, tryptophan and trypto-
phan-metabolites in patients with ESLD compared to healthy volunteers
Patients who died during the first year post-transplant due to graft failure or sepsis (group-I, n=15) and patients who survived more than one year (group-II, n=74) had significantly higher pre-transplant serum levels of phenylalanine, kynurenine, kynurenic acid, and a higher kynurenine/tryptophan ratio than HCs (p0.001 for all measurements) (Figure 1a, 1b, 1d and 1f) . Serum levels of pre-transplant tryptophan and quinolinic acid were significantly higher in group-I than in HCs (p0.001 for all measurements) and were similar in group-II and HCs (p=0.92 and 0. 
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Sensitivity and specificity of risk factors in the two patients groups
We performed ROC curve analysis of pre-and post-transplant significant parameters to calculate cut-off values. The sensitivity and specificity of all significant parameters were calculated and depicted in Table 2 . Day 10 post-transplant serum phenylalanine >68 µmol/l showed a sensitivity of 69%, specificity of 93%, positive predictive value (PPV) of 56% and negative predictive value (NPV) of 90%. Serum bilirubin >6 mg/dl on day 5 post-transplant had a sensitivity of 75%, specificity of 81%, PPV of 46% and NPV of 94%.
Regression analysis of significant parameters
We calculated odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between significant parameters and mortality using uni-and multi-variate logistic regression models. Univariate regression analyses showed that day 5 posttransplant serum bilirubin, day 5 and 10 posttransplant phenylalanine and pretransplant serum kynurenine (p<0.001 for all investigations) are most significant associated factors of one-year mortality (Table 3) . Multivariate regression analysis showed that day 10 post-transplant serum phenylalanine > 68 µmol/L (p<0.001: OR=4.045 CI 1.250-13.095) and day 5 post-transplant serum bilirubin> 6 mg/dl (p=0.005: OR=7.121 CI 2.263-22.403) are significant associated factors of one-year mortality (Table 3) .
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Discussion
The aim of this study was to evaluate the pre-and early post-transplant measurement of phenylalanine, tryptophan and tryptophan metabolites (kynurenine, kynurenic acid and quinolinic acid) in liver transplant recipients in relation to the one-year posttransplant patient survival. High phenylalanine plasma levels or phenylalanine/tyrosine ratios were reported in patients with HIV-1, Dengue fever, HCV, CMV infection (9, (19) (20) (21) and inflammatory responses (15, (22) (23) (24) . The reason for this phenomenon is unclear. However, all these clinical conditions are known to be linked with inflammation and immune activation (24) .
IDO degrades the essential amino acid tryptophan into kynurenine and other downstream metabolites (13). Acquired immunity is impaired in hemodialysis patients and
Eleftheriadis et al. suggested that this is the result of increased IDO activity which is inducible by inflammation (12) . In a new study involving trauma and sepsis patients, Ploder et al. showed that, compared to healthy controls, patients exhibited increased kynurenine concentrations, kynurenine/tryptophan ratios, and TNF-α, IL-6 and neopterin plasma levels (25) . Compared to the survivors, the non-survivors showed higher concentrations of kynurenine, neopterin, TNF-α and IL-6, as well as a higher kynurenine/tryptophan ratio (25) . IDO has previously been shown to be associated with outcomes of organ transplantation (9, 10, (26) (27) (28) (29) (30) . Weng et al. indicated that the expression of the IDO gene in peripheral blood tightly correlated with the severity of acute rejection in a rat liver transplant model (30) . Tryptophan metabolites in the kynurenine pathway induce immunosuppression (31) (32) (33) (34) . These results imply that increased tryptophan degradation in patients is due to activated IDO, which most probably is a consequence of a host defense response. These findings support a possible
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14 role of IDO in the development of immunodeficiency that predisposes to death in transplanted patients (25) .
In this study, we showed for the first time the association of increased amino acid and amino acid metabolites serum levels with mortality from sepsis and/or graft failure during the first year post-transplant. Patients at risk of death showed significantly increased serum levels of phenylalanine and tryptophan metabolites pre-and early posttransplant. Statistical analysis indicated the closest association of the rate of death with pre-and early post-transplant phenylalanine, kynurenine and kynurenic acid serum levels.
We found the optimal cut-off value of pre-transplant kynurenine at 4. 8 µmol/L, kynurenic acid at 1.8 µmol/L and phenylalanine at 70 µmol/L. These cut-off values showed a sensitivity and specificity of 68% and 77% for kynurenine, 63% and 73% for kynurenic acid and 69% and 70% for phenylalanine for the association with the one year post-transplant mortality rate. As expected, post-transplant parameters especially phenylalanine and serum bilirubin were stronger associated with one year mortality than pre-transplant parameters.
Prediction of post-transplant mortality following organ transplantation is essential to save the patient and the organ, and would initiate more care to rescue patients at risk.
Sensitivity and specificity of the analyzed parameters were not excellent but acceptable. However, the high negative predictive values (92%, 90%, and 91%, respectively) reliably allow the identification of patients likely not to experience mortality. These results also indicate that liver dysfunction is associated with a strongly activated catabolic pathway of tryptophan degradation.
In summary, disturbance in pre-and early post-transplant metabolism of amino acids and their metabolites correlate with one-year mortality rate in liver allograft recipients.
In conclusion, we have shown that pre-and early post-transplant serum levels of phenylalanine and metabolites of tryptophan are significantly sensitive and specific parameters with high NPV for post-transplant mortality in liver transplant recipients.
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